The Medical Technology Stock Letter (“MTSL”) is published 24 times per year, sent either electronically and/or via print mail. In addition to our redesigned and enhanced website — BioInvest.com — MTSL now provides more timely updates, whitepapers and breaking news than ever before. We offer unique perspectives on medical trends, portfolio companies and focus on diversification and risk management strategies to help investors profit from today’s market volatility. Our philosophy of buying carefully selected biotech stocks at attractive prices and holding them for the long-term hasn’t changed. What has changed is our ability to make MTSL a more valuable tool for today’s discerning investor.
For the Corporate or Institutional Investor**
*Printed copies are $60 more per year.
**Limited to 50 users per group subscription.